Today, Marvin Ventrell, NAATP CEO represented the NAATP membership at an invitation-only event at the White House to celebrate passage of items of importance to the substance use disorder field contained in the Omnibus spending bill passed in December of 2022. Specifically, elimination of the X waiver for buprenorphine prescribers and the additional funding for numerous SAMHSA programs were highlighted.
Along with leaders in the field, the Director of the Office of National Drug Control Policy attended. On behalf of President Biden, Dr. Gupta thanked the organizations in attendance for their support of the policies and the legislation. He said passage of these important priorities will improve access to care far into the future.
HHS Assistant Secretary and SAMHSA Director, Dr. Delphin Rittman also attended and commented on the value to the field of the additional resources. She also expressed her appreciation and that of Secretary Becerra.
“I’m appreciative of the commitment of our government partners who are striving to improve access to care for patients.” said Ventrell. “I am also proud that NAATP is seen as a critical participant impacting substance use disorder policy in the United States,” he commented. “It takes a major effort to make this kind of substantial progress and we’re delighted to play a significant role.”
On the left: Dr. Rahul Gupta, ONDCP Director, Anne Milgram, Administrator of the DEA, Dr. Miriam Delphin-Rittmon, HHS Assistant Secretary and SAMHSA Director, and other leaders in the SUD field pose for a picture at the White House Removing Barriers to Treatment event on January 24th, 2023.
On the right: Dr. Miriam Delphin-Rittmon, HHS Assistant Secretary and SAMHSA Director with Marvin Ventrell, NAATP CEO.